Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Moazedi-Fuerst, FC; Lackner, A; Kreuzer, SM; Eller, K; Odler, B; Kovacs, G; Flick, H; Talakic, E; Hermann, J; Venhoff, N; Venhoff, A; Hafner, F; Brodmann, M; Jud, P; Yazdani-Biuki, B; Husic, R; Salmhofer, W; Stradner, MH; Graninger, WB; Thiel, J; Brezinschek, HP.
Successful long-term systemic sclerosis treatment by high-frequent low-dose B cell-depleting therapy.
J Autoimmun. 2024; 147: 103246
Doi: 10.1016/j.jaut.2024.103246
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Moazedi-Fürst Florentine
- Co-Autor*innen der Med Uni Graz
- Brezinsek Hans-Peter
- Brodmann Marianne
- Eller Kathrin
- Flick Holger
- Graninger Winfried
- Hafner Franz
- Hermann Josef
- Husic Rusmir
- Jud Philipp
- Kovacs Gabor
- Lackner Angelika
- Odler Balazs
- Salmhofer Wolfgang
- Stradner Martin Helmut
- Talakic Emina
- Thiel Jens
- Yazdani-Biuki Babak
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- OBJECTIVES: Systemic sclerosis (SSc) is a multiorgan disease with a 10-year mortality rate of up to 50 %. B cell-depleting therapy with rituximab (RTX) appears effective in SSc treatment, but data from randomized controlled trials (RCTs) are lacking, and the frequency and dosage of RTX in SSc have no consensus. We aimed to evaluate the long-term efficacy and safety of quarterly RTX administration in SSc. METHODS: This study retrospectively analyzed 40 patients with SSC treated with RTX twice within 14 days every 3 months from 2010 to 2020. The patients fulfilled the LeRoy and the American College of Rheumatology/European League Against Rheumatism Criteria for SSc. Modified Rodnan skin score (mRSS), lung function test results, and serum immunoglobulin (IgG, IgA, and IgM) concentrations were analyzed. RESULTS: A total of 40 patients with SSc received RTX over a median time of 3.9 years (range: 1-10 years). The median mRSS (baseline: 19, 24 months: 16, p < 0.001) demonstrated a significant improvement, and the predicted forced vital capacity was stable. No new or unexpected safety signals, especially regarding treatment-related infectious adverse events, were observed. Immunoglobulin concentrations were within normal range, and specific antibodies to pneumococcal polysaccharides were preserved despite long-term B cell-depleting therapy. None of the patients died during the observation period of up to 10 years. CONCLUSION: SSc was effectively and safely treated with low-dose RTX quarterly. RCTs are warranted to validate the advantage of continuous B cell depletion by quarterly low-dose RTX administration compared to other treatment intervals.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Scleroderma, Systemic - mortality, immunology, therapy, drug therapy
- Female - administration & dosage
- Male - administration & dosage
- Middle Aged - administration & dosage
- B-Lymphocytes - immunology
- Rituximab - therapeutic use
- Retrospective Studies - administration & dosage
- Lymphocyte Depletion - administration & dosage
- Adult - administration & dosage
- Treatment Outcome - administration & dosage
- Aged - administration & dosage
- Find related publications in this database (Keywords)
- Systemic sclerosis
- Rituximab
- Mycophenolate mofetil
- SSC -Interstitial lung disease (ILD)